Aquestive Therapeutics Inc AQST
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AQST is a good fit for your portfolio.
News
-
Thinking about buying stock in Akebia Therapeutics, Boeing, Aquestive Therapeutics, General Electric, or Canoo?
-
Thinking about buying stock in SoundHound AI, Aquestive Therapeutics, Akebia Therapeutics, Kaival Brands, or Lufax?
-
Thinking about buying stock in Aquestive Therapeutics, Spruce Biosciences, Vale, Marathon Digital Holdings, or Cybin?
-
Thinking about buying stock in Aadi Bioscience, Bitdeer Technologies, Aquestive Therapeutics, 89bio, or Energem?
-
Thinking about buying stock in Monopar Therapeutics, Aquestive Therapeutics, NXU, SeaStar Medical, or TDCX?
-
Thinking about buying stock in Coffee Holding Co., Aquestive Therapeutics, Snowflake Inc, Mesoblast, or Modular Medical?
-
Aquestive Therapeutics Shares Rise 12% on Anaphylm Trial Timeline
Trading Information
- Previous Close Price
- $3.85
- Day Range
- $3.82–4.05
- 52-Week Range
- $1.15–6.23
- Bid/Ask
- $3.90 / $4.00
- Market Cap
- $352.67 Mil
- Volume/Avg
- 2.4 Mil / 2.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.66
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 135
- Website
- https://www.aquestive.com
Comparables
Valuation
|
Metric
|
AQST
|
ICVX
|
EWTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 3.30 | 3.67 |
Price/Sales | 4.66 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AQST
|
ICVX
|
EWTX
|
|---|---|---|---|
Quick Ratio | 1.77 | 17.59 | 18.98 |
Current Ratio | 2.24 | 18.06 | 19.50 |
Interest Coverage | −2.21 | — | — |
Quick Ratio
AQST
ICVX
EWTX
Profitability
|
Metric
|
AQST
|
ICVX
|
EWTX
|
|---|---|---|---|
Return on Assets (Normalized) | −7.96% | −29.30% | −24.36% |
Return on Equity (Normalized) | — | −31.87% | −25.87% |
Return on Invested Capital (Normalized) | — | −34.69% | −29.82% |
Return on Assets
AQST
ICVX
EWTX
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Wfbyfwypb | Hsdqjb | $70.5 Bil | |
ZTS
| Zoetis Inc Class A | Fpwwdrljf | Zzmy | $69.4 Bil | |
HLN
| Haleon PLC ADR | Tvthjlss | Tlrhp | $36.6 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Nxtdsgym | Rwsq | $14.9 Bil | |
VTRS
| Viatris Inc | Rmfxkzqh | Pyf | $13.2 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Pfxtlwmn | Wmcbw | $12.0 Bil | |
CTLT
| Catalent Inc | Bmryhwkp | Mmffbs | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Zbwjkcltt | Tdzt | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Hzfjdxhv | Bzwcg | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Mrrltwj | Dvcnyps | $3.4 Bil |